Immuron (IMRN) Cash from Investing Activities (2016 - 2024)
Immuron (IMRN) posted quarterly Cash from Investing Activities of $35309.1 for Q4 2024, down 64.67% year-over-year from $99932.2 in Q1 2024, and down 64.67% quarter-over-quarter from $99932.2 in Q4 2023.
Immuron (IMRN) Cash from Investing Activities (2016 - 2024) Analysis & Trends
Immuron's Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $35309.1 for Q4 2024.
- In Q4 2024, Cash from Investing Activities fell 64.67% year-over-year to $35309.1; the TTM figure through Dec 2024 stood at -$2.5 million (up 1.43% YoY), while the FY2025 annual figure was -$2.9 million, down 985.46% from the prior year.
- Cash from Investing Activities for Q4 2024 stood at $35309.1, down from $99932.2 in the prior quarter.
- The five-year high for Cash from Investing Activities was $99932.2 in Q4 2023, with the low at -$2.6 million in Q4 2022.
- The 5-year median for Cash from Investing Activities is $5550.2 (2021), against an average of -$492615.7.
- The sharpest annual moves came in 2021 and 2022: Cash from Investing Activities surged 1943.91% in 2021, then sank 47009.79% in 2022.
- Immuron's Cash from Investing Activities stood at -$301.0 in 2020, then soared by 1943.91% to $5550.2 in 2021, then tumbled by 47009.79% to -$2.6 million in 2022, then soared by 103.84% to $99932.2 in 2023, then sank by 64.67% to $35309.1 in 2024.
- Business Quant data shows IMRN's Cash from Investing Activities at $35309.1 in Q4 2024, $99932.2 in Q4 2023, and -$2.6 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Immuron | 6.75 Mn | 6.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2024 | 35,309.08 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2023 | 99,932.25 |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2022 | -2.60 Mn |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2021 | 5,550.16 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2020 | -301.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2019 | -605.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2018 | 39.00 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2017 | -1,698.97 |
| Dec 31, 2016 | 1,416.72 |
| Dec 31, 2016 | 1,416.72 |